Circio Holding (formerly known as Targovax) is a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.